Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference
source: pixabay.com

Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference

According to a story from globenewswire.com, the biopharmaceutical company Inventiva is scheduled to present the findings from a recent phase IIa clinical trial at the upcoming 16th Annual WorldSymposium™ which is…

Continue Reading Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference
Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)
jarmoluk / Pixabay

Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)

Inventiva has recently completed Phase IIa of their clinical trial of odiparcil, a drug made for the treatment of mucopolysaccharidosis type VI (MPS VI). Iventiva is very excited about the…

Continue Reading Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)
First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study
felixioncool / Pixabay

First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study

According to a story from Benzinga, the biopharmaceutical company Inventiva has recently announced that it has recruited the first patients in a study of biomarkers in Maroteaux-Lamy syndrome. The study…

Continue Reading First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study

UPDATE: Trump Admin Reconsiders Decision to Deport Migrants Receiving Life-Saving Treatment 

Last week, we spotlighted a New York Times story about how under the Trump Administration’s new immigration policy, six migrants undergoing lifesaving treatments would be abruptly deported; including a young woman…

Continue Reading UPDATE: Trump Admin Reconsiders Decision to Deport Migrants Receiving Life-Saving Treatment 

NYT: Woman Receiving Lifesaving Rare Disease Treatment is Facing Deportation 

The New York Times reported that under the Trump Administration's new immigration policy, six migrants undergoing lifesaving treatments have received deportation letters; including a young woman battling a rare disease.…

Continue Reading NYT: Woman Receiving Lifesaving Rare Disease Treatment is Facing Deportation 

Patient Recruitment Completed for Phase 2 Study of Mucopolysaccharidosis VI Drug Candidate

According to a press release from the French biotechnology company Inventiva, the company has completed recruitment for a phase 2 clinical trial evaluating its experimental mucopolysaccharidosis VI drug, odiparcil. About…

Continue Reading Patient Recruitment Completed for Phase 2 Study of Mucopolysaccharidosis VI Drug Candidate

Experimental MPS VI Drug Granted Rare Pediatric Disease Designation

A recent press release from the French biopharmaceutical company Inventiva announced that the Food and Drug Administration (FDA) had granted the company's experimental mucopolysaccharidosis VI (MPS VI) drug odiparcil rare…

Continue Reading Experimental MPS VI Drug Granted Rare Pediatric Disease Designation
This Just In: India Never Implemented their Rare Disease Policy as Promised
Source: Pixabay.com

This Just In: India Never Implemented their Rare Disease Policy as Promised

We all got really excited last year when India implemented a new plan to benefit rare disease patients. It was called the National Rare Disease Policy. Basically, it put 12.86…

Continue Reading This Just In: India Never Implemented their Rare Disease Policy as Promised
Close Menu